Xylem (NYSE:XYL) Stock Gets Price Target Reduction from BNP Paribas Exane

Key Points

• BNP Paribas Exane cut Xylem’s price target from $145 to $135 but maintained an “outperform” rating, implying approximately 53% upside from the stock’s $88.13 price.
• Xylem’s latest quarter fell slightly short of expectations, with EPS of $1.44 versus $1.45 expected and revenue of $2.20 billion versus $2.28 billion forecast; revenue declined 3% year over year.
• Analyst sentiment is mixed: JPMorgan downgraded the stock to “neutral,” while Goldman Sachs maintained a “buy” rating. Overall, analysts hold a “Moderate Buy” consensus with an average target of $129.50.

Xylem (NYSE:XYL - Get Free Report) had its price target cut by investment analysts at BNP Paribas Exane from $145.00 to $135.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an "outperform" rating on the industrial products company's stock. BNP Paribas Exane's target price suggests a potential upside of 53.18% from the company's current price.

Other equities research analysts also recently issued research reports about the company. Mizuho set a $99.00 target price on Xylem in a report on Wednesday. JPMorgan Chase & Co. downgraded shares of Xylem from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $118.00 to $90.00 in a research report on Wednesday. Weiss Ratings reissued a "hold (c)" rating on shares of Xylem in a research note on Wednesday, August 5th. The Goldman Sachs Group restated a "buy" rating and issued a $138.00 price target (down from $160.00) on shares of Xylem in a report on Wednesday. Finally, Robert W. Baird set a $123.00 price objective on Xylem in a report on Wednesday. Ten equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $129.50.

Xylem Price Performance

Shares of NYSE:XYL traded down $4.73 during trading on Wednesday, reaching $88.13. The stock had a trading volume of 6,043,065 shares, compared to its average volume of 2,131,106. The stock has a market cap of $20.58 billion, a PE ratio of 20.98, a PEG ratio of 1.75 and a beta of 1.00. The business has a fifty day moving average price of $106.50 and a 200-day moving average price of $118.31. Xylem has a 1-year low of $87.40 and a 1-year high of $154.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.61.

Xylem (NYSE:XYL - Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The industrial products company reported $1.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.45 by ($0.01). The business had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.28 billion. Xylem had a return on equity of 11.77% and a net margin of 11.15%. The firm's revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.37 earnings per share. On average, equities analysts forecast that Xylem will post 5.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Renaissance Investment Group LLC increased its stake in shares of Xylem by 5.8% in the third quarter. Renaissance Investment Group LLC now owns 88,230 shares of the industrial products company's stock worth $8,935,000 after acquiring an additional 4,823 shares during the last quarter. Soltis Investment Advisors LLC acquired a new stake in Xylem during the third quarter worth $6,895,000. Choreo LLC acquired a new position in Xylem during the third quarter worth $248,000. North Star Investment Management Corp. raised its position in Xylem by 21.4% in the 3rd quarter. North Star Investment Management Corp. now owns 1,701 shares of the industrial products company's stock valued at $172,000 after purchasing an additional 300 shares during the last quarter. Finally, William Mack & Associates Inc. acquired a new position in Xylem during the 3rd quarter worth $25,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Xylem

Here are the key news stories impacting Xylem this week:

• Positive Sentiment: Third-quarter adjusted EPS increased to $1.44 from $1.37 a year earlier, while orders reportedly rose 10%, suggesting some underlying demand resilience. However, these gains were not enough to offset the revenue shortfall and weaker guidance. Xylem Q3 2026 results
• Positive Sentiment: Stifel Nicolaus retained a “buy” rating with a $114 price target, while Oppenheimer maintained “outperform” at $135. These targets imply substantial recovery potential if Xylem executes its restructuring and business reset. Stifel Nicolaus rating
• Neutral Sentiment: Xylem plans divestitures and a segment restructuring as part of a portfolio reset. The changes could improve focus and profitability over time, but they also introduce execution risk and may weigh on results in the near term. Xylem outlook and restructuring
• Negative Sentiment: Revenue fell 3% year over year to $2.20 billion, about $80 million below expectations, and EPS missed consensus. Weak metering demand and project timing pressured sales. Xylem Q3 revenue miss
• Negative Sentiment: Management lowered its 2026 revenue and profit outlook and issued a weak fourth-quarter forecast, signaling that near-term headwinds are more severe than previously expected. Xylem lowered outlook
• Negative Sentiment: JPMorgan downgraded Xylem to “neutral” and cut its price target to $90 from $118. RBC also reduced its target to $125, and Oppenheimer lowered its target to $135, reflecting broad estimate revisions. JPMorgan Xylem downgrade
• Negative Sentiment: Put-option volume surged to more than four times its average, indicating increased hedging or bearish speculation. A law firm also announced an investigation into potential securities-law violations following the earnings-related losses. Xylem investigation notice

Xylem Company Profile

Xylem Inc NYSE: XYL is a global water technology company that develops products and services for the transportation, treatment, testing and efficient use of water and wastewater. Its offerings support municipal water and wastewater utilities, industrial customers, commercial facilities and residential applications.

The company's products and solutions include water and wastewater pumps, treatment systems, dewatering equipment, smart meters, monitoring and control technologies, leak detection tools, and data-driven analytics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.